Health Robotics Wins Public Tender at National Cancer Institute of Milan, Defeating Former Partner Loccioni

Bozen, Sud-Tirol, Italy – April 27th, 2012.

Health Robotics today announced its most recent competitive win through a public tender purchasing process at prestigious National Cancer Institute of Milan, where it defeated its former development partner Loccioni by a margin of 52 to 26 points. http://www.health- robotics.com/smartedit/downloads/en/avviso_aggiudicazione_farmacia.pdf

Gaspar DeViedma, Health Robotics’ Executive Vice President, stated: “We are very pleased to have leapfrogged over Loccioni’s older generation products and defeat them so clearly at the National Cancer Institute of Milan, as judged by the publicly-available official scores of the tender process. We have now reclaimed the Italian market leadership position by replacing Loccioni as the local market frontrunner and offering fully automated I.V. robots in Italy. Health Robotics’ 2nd Generation robots [unlike Loccioni’s older I.V. robots] do not require Italian pharmacists to manually cap and label chemotherapy syringes and IV bags.”

Health Robotics had been absent from the Italian market until 1 year ago by virtue of a prior agreement with its former CytoCare development partner Loccioni/AEA to concentrate on the global market while Loccioni exclusively provided I.V. robots to hospitals in Italy. In 2007, Health Robotics sub-licensed to Loccioni an old version of CytoCare and its patents (subsequently renamed APOTECAchemo by Loccioni), while it continued to separately develop 2nd Generation technology (i.v.STATION) that has eventually proven to leapfrog its original joint-development with Loccioni.

Concluded Mr. DeViedma: “First generation robots such as Loccioni’s APOTECAchemo and its other competitors1 are generally characterized by semi-automated I.V. sterile compounding tasks, large size and weight (up to 210 square feet and 6,700 pounds), slow speed/throughput [5 to 20 doses/hour], high price ($1M+), and 3 to 5 years’ R.O.I. In contrast, 2nd Generation Robots like i.v.STATION and i.v.STATION ONCO are fully automated, offering 3 times faster speed and throughput, for less than half the price, size, and weight, while they deliver payback periods [R.O.I.] of less than 1 year.”

About National Cancer Institute, Milan, Italy: Opened in 1928, the National Cancer Institute in Milan (IRCCS Foundation) was recognized as a Scientific Institute in 1939. It approximately employs 2.000 FTEs, operating 482 beds, 54 day-care beds, and 14.000 annual admissions. The National

1 Competitor’s Announcements: MDS (now Fresenius Kabi) [2002], RIVA/Intelligent Hospital Systems [2005], For Health Technologies (now Baxa/Baxter) [2008], Panasonic [2009], Loccioni’s APOTECAchemo [2010] (under license from Health Robotics).

Cancer Institute in Milan is considered a center of excellence at the national level for the cure of all types of cancer, including rare tumors, http://www.istitutotumori.mi.it/

About Health Robotics: Founded in 2006, Health Robotics is the undisputed global leading supplier of life-critical intravenous medication robots, winning 100% of all worldwide I.V. Robots publicly announced purchases in 2010 and 2011, and providing over 250 hospital installations in 5 continents with robotics-based technology and clinical software automation solutions. Health Robotics’ world- leading solutions CytoCare® and i.v.STATION® ONCO [hazardous IVs], i.v.STATION® [non- hazardous IVs], i.v.SOFT® [workflow engine for sterile compounding], OMM® [Oncology Medication Management], MEDarchiver® [life-critical clinical information system], and TPNstationTM [totally-automated parenteral nutrition] have and will greatly contribute to ease hospitals’ growing pressures to improve patient safety, increase throughput and contain costs. Through the effective and efficient production of sterile, accurate, tamper-evident and ready- to-administer IVs, Health Robotics’ products help hospitals eliminate life-threatening drug and diluent exchange errors, decrease other medical mistakes and sterility risks, work more efficiently, reduce waste and controlled substances’ diversion, and diminish the gap between rising patient volume/acuity and scarce medical, nursing, and pharmacy staff.

Download in PDF Format :

Health Robotics – Pharma Tech PR April 27,2012

Contact Us Call Us